Assessing uptake of the macular degeneration core outcome set in clinical trials: a cross-sectional study
No discernible patterns in COS usage for MD trials were observed. We recommend further collaboration between regulators and COS developers to help with COS uptake. Additionally, we suggest that further studies analyse adherence to COSs in respect to regulatory recommendations.
Authors
- Kimberly Magana (ORCID: https://orcid.org/0000-0002-3157-6892)
- Kyle Fitzgerald (ORCID: https://orcid.org/0000-0001-6253-3644)
- Trevor Magee (ORCID: https://orcid.org/0000-0002-1753-3044)
- Jay Modi (ORCID: https://orcid.org/0000-0002-7475-2040)
- Shaelyn Ward (ORCID: https://orcid.org/0000-0002-4127-7562)
- Garrett Jones (ORCID: https://orcid.org/0000-0002-3772-4518)
- Alicia Ito Ford (ORCID: https://orcid.org/0000-0002-6866-2639)
- Griffin Hughes (ORCID: https://orcid.org/0000-0003-3863-7915)
- Eli P Oldham
- Matthew Vassar
- R. Hunter Hall
Institutions
- Oklahoma State University Center for Health Sciences (US)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-104705
- Primary Topic
- Delphi Technique in Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00